Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria
GlaxoSmithKline Plc and Novartis AG will contribute research funds to an almost $4 billion global effort to combat malaria as drug-resistant strains of the disease threaten to undo years of progress.